Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, will announce its third quarter 2026 financial results on November 4. Following the release, senior management will hold a conference call to discuss the results and provide business updates. The company is advancing several cardiac muscle-related drug candidates, including the approved MYQORZO® for obstructive hypertrophic cardiomyopathy and plans to submit a supplemental application for non-obstructive HCM treatment. Investors can access the webcast via Cytokinetics’ website, with a replay available for six months.
Cytokinetics shares trade at USD 62.89 on Pluang as of Oct 22, 2026, down 1.66% for the day. The stock's market cap stands at $8.89 billion, with a 52-week range between $54.76 and $87.26. Investors hold the stock for an average of 20 days on the platform.
An executive at Cytokinetics sold 3,500 shares worth about $224,035 as the company's heart disease drug Myqorzo expands in the U.S. and gains approvals in Canada, Germany, and the U.K. Myqorzo has strong prescription growth, accounting for over 40% o...
Cytokinetics, a cardiovascular biopharmaceutical company, granted stock options for 60,465 shares and 40,084 restricted stock units (RSUs) to 29 new employees hired in September and October 2026. The RSUs vest over three years, while the stock option...
Health Canada has approved MYQORZO (aficamten) for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as NYHA class II-III. MYQORZO is an oral drug that reduces heart muscle contractility and obstruction, impro...
